Drugs | Chemical structure | Target | Tumor types | Phase | Ref. |
---|---|---|---|---|---|
Foretinib (31) |
| VEGFR2/3, c-Met, Tie-2 | Gastric tumor and head/neck tumor | II | [94] |
Golvatinib (32) |
| VEGFR2, c-Met | Head and neck tumor, liver tumor | II | [94] |
Dovitinib (33) |
| FLT3, FGFR1/3, VEGFR1,2,3, EGFR, c-Met | Solid tumor | IV | [95] |
Tivozanib (34) |
| VEGFR1/2/3, c-Met, PDGFR, c-Kit | Advanced renal cell carcinoma | III | [96] |
BMS-794833 (35) |
| VEGFR2, c-Met, Ron, Axl, FLT3 | Gastric tumor | I | [93] |
BMS-777607 (36) |
| VEGFR, c-Met, Ron, Axl, | Advanced solid tumor | II | [97] |
MGCD265 (37) |
| VEGFR1/2, c-Met, Ron | Non-small cell lung tumor | II | [98] |
AC480 (38) |
| VEGFR2, HER1/2/4, c-Kit, Met, Lck | Advanced solid tumor | I | [99] |
CP-724714 (39) |
| HER2, EGFR, VEGFR2, c-Met | Advanced solid tumor | II | [100] |
AMG-458 (40) |
| VEGFR2, c-Met | Solid tumor | Non-medicinal | [101] |